Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that the FDA has approved Combivent Respimat (ipratropium bromide and ...
Ipratropium bromide 20mcg, albuterol 100mcg (equivalent to 120mcg albuterol sulfate); per actuation; inhalation spray; CFC-free. Based on studies, ipratropium bromide appears to inhibit vagally ...
Boehringer Ingelheim Pharmaceuticals, Inc. announced that the US Food and Drug Administration (US FDA) has approved Combivent Respimat, a new, propellant-free inhaler product that uses a slow-moving ...
RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday. BI Pharmaceuticals announced the launch of ...
ATLANTA, Georgia — Patients with chronic obstructive pulmonary disease (COPD) experience few adverse events and discontinuations when treated with an ipratropium plus albuterol inhalation spray (CVT-R ...
Statement: “Big drug companies charge as little as $7 for an inhaler overseas and nearly $500 for the exact same one here in the US.” Are Americans paying nearly $500 for an inhaler that would cost ...
Connecticut-based Boehringer Ingelheim Pharmaceuticals Inc. has been hit with a prospective class action lawsuit that alleges its Combivent asthma inhaler provides far less than the number of ...
Four U.S. senators, led by Bernie Sanders, I-Vt., have sent letters to the four largest inhaler manufacturers – AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK) and Teva Pharmaceuticals – ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback